secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quoin Pharmaceuticals, Ltd. (QNRX)
CIK:        0001671502
Form:       8-K
Filed at:   2025-06-25T23:59:59+00:00
Accession:  0001104659-25-062406
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Quoin Pharma receives FDA Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome
--------------------------------------------------------------------------------

- FDA granted Rare Pediatric Disease Designation (RPDD) on June 24, 2025 for QRX003.
- QRX003 is Quoin's lead asset for treating Netherton Syndrome, a rare genetic disorder.
- RPDD makes QRX003 eligible for priority review and a Rare Pediatric Disease Priority Review Voucher if approved.
- Quoin is a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases.
- The designation underscores the unmet need in Netherton Syndrome with no approved therapies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671502/000110465925062406/0001104659-25-062406-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671502/000110465925062406/tm2518927d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-062406

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer